Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegylated Interferon Alfa-2b Plus Ribavirin for Dual Chronic Hepatitis B and Delta
NCT00117533Phase 4Unknown
- Sponsor
- National Taiwan University Hospital
- Start
- Sep 2005
- Modality
- Polymer-based Nanoparticles, Orthosteric Ligands, Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of peginterferon alfa-2b and ribavirin in hepatitis D (HDV) and hepatitis B (HBV), sponsored by National Taiwan University Hospital. Primary endpoint: Sustained Virologic Response of HDV. Status: unknown.
02
Drugs
peginterferon alfa-2bribavirin
03
Conditions
hepatitis D (HDV)hepatitis B (HBV)
Beyond the preview
Go deeper on NCT00117533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00117533.